Lilly Halts Development of Semagacestat for Alzheimer’s Disease
Eli Lilly and Company (NYSE: LLY) will halt development of semagacestat, a gamma secretase inhibitor being studied as a potential treatment for Alzheimer’s disease,
Original Source of Lilly Halts Development of Semagacestat for Alzheimer’s Disease



